141 related articles for article (PubMed ID: 23225443)
1. Phase I study of combination chemotherapy consisting of paclitaxel, cisplatin, and S-1 in patients with unresectable gastric cancer (KOGC-02).
Takahashi T; Saikawa Y; Fukuda K; Funakoshi S; Kawakubo H; Takeuchi H; Takaishi H; Kitagawa Y
Anticancer Res; 2012 Dec; 32(12):5401-6. PubMed ID: 23225443
[TBL] [Abstract][Full Text] [Related]
2. A phase I study of triplet combination chemotherapy of paclitaxel, cisplatin and S-1 in patients with advanced gastric cancer.
Kimura Y; Yano H; Imamura H; Fujitani K; Imano M; Tokunaga Y; Matsuoka M; Kurokawa Y; Shimokawa T; Takiuchi H; Tsujinaka T; Furukawa H
Jpn J Clin Oncol; 2013 Feb; 43(2):125-31. PubMed ID: 23225911
[TBL] [Abstract][Full Text] [Related]
3. A phase I study of S-1 administration and a 24-h infusion of cisplatin plus paclitaxel in patients with advanced gastric cancer.
Iwase H; Shimada M; Tsuzuki T; Okeya M; Kobayashi K; Hibino Y; Watanabe H; Goto H
Anticancer Res; 2006; 26(2B):1605-9. PubMed ID: 16619579
[TBL] [Abstract][Full Text] [Related]
4. Phase I study of a combination of s-1 and weekly paclitaxel in patients with advanced or recurrent gastric cancer.
Ueda Y; Yamagishi H; Ichikawa D; Morii J; Koizumi K; Kakihara N; Shimotsuma M; Takenaka A; Yamashita T; Kurioka H; Nishiyama M; Morita S; Nakamura K; Sakamoto J
Oncology; 2005; 69(3):261-8. PubMed ID: 16138002
[TBL] [Abstract][Full Text] [Related]
5. Phase I/II trial of combination therapy with S-1 and weekly paclitaxel in patients with unresectable or recurrent gastric cancer.
Inada S; Tomidokoro T; Fukunari H; Sato T; Hatano T; Nishimura A; Kawauchi Y; Nikkuni K; Shimizu T; Sato T; Yanagi M; Takahashi S; Yoshida H; Sugita M; Hayashi T
Cancer Chemother Pharmacol; 2009 Jan; 63(2):267-73. PubMed ID: 18379784
[TBL] [Abstract][Full Text] [Related]
6. A phase I study of combination therapy of the oral fluorinated pyrimidine compound S-1 with low-dose cisplatin twice-a-week administration (JFMC27-9902 Step2) in patients with advanced gastric cancer using a continual reassessment method.
Morita S; Nakata B; Tsuji A; Mitachi Y; Shirasaka T; Saji S; Ohashi Y; Sakamoto J; Hirakawa K
Jpn J Clin Oncol; 2007 Dec; 37(12):924-9. PubMed ID: 18211983
[TBL] [Abstract][Full Text] [Related]
7. A multicenter phase II study of biweekly paclitaxel and S-1 combination chemotherapy for unresectable or recurrent gastric cancer.
Nakajo A; Hokita S; Ishigami S; Miyazono F; Etoh T; Hamanoue M; Maenohara S; Iwashita T; Komatsu H; Satoh K; Aridome K; Morita S; Natsugoe S; Takiuchi H; Nakano S; Maehara Y; Sakamoto J; Aikou T;
Cancer Chemother Pharmacol; 2008 Nov; 62(6):1103-9. PubMed ID: 18317763
[TBL] [Abstract][Full Text] [Related]
8. A phase II multi-center study of triple therapy with paclitaxel, S-1 and cisplatin in patients with advanced gastric cancer.
Iwase H; Shimada M; Tsuzuki T; Ina K; Sugihara M; Haruta J; Shinoda M; Kumada T; Goto H
Oncology; 2011; 80(1-2):76-83. PubMed ID: 21659786
[TBL] [Abstract][Full Text] [Related]
9. A phase I study of bi-weekly combination therapy with S-1 and docetaxel for advanced or recurrent gastric cancer.
Rino Y; Takanashi Y; Yukawa N; Saeki H; Wada H; Kanari M; Yamada R; Satoh T; Yamamoto N; Imada T
Anticancer Res; 2006; 26(2B):1455-62. PubMed ID: 16619558
[TBL] [Abstract][Full Text] [Related]
10. Multicenter phase II trial of S-1, paclitaxel and cisplatin triplet combination chemotherapy in patients with advanced gastric cancer.
Kim JY; Do YR; Park KU; Kim JG; Chae YS; Kim MK; Lee KH; Ryoo HM; Bae SH; Baek JH; Song HS
Cancer Chemother Pharmacol; 2011 Mar; 67(3):527-32. PubMed ID: 20461377
[TBL] [Abstract][Full Text] [Related]
11. A multicenter phase II study of combined chemotherapy with docetaxel, cisplatin, and S-1 in patients with unresectable or recurrent gastric cancer (KDOG 0601).
Koizumi W; Nakayama N; Tanabe S; Sasaki T; Higuchi K; Nishimura K; Takagi S; Azuma M; Ae T; Ishido K; Nakatani K; Naruke A; Katada C
Cancer Chemother Pharmacol; 2012 Feb; 69(2):407-13. PubMed ID: 21796483
[TBL] [Abstract][Full Text] [Related]
12. Phase II study of S-1, docetaxel and cisplatin combination chemotherapy in patients with unresectable metastatic gastric cancer.
Sato Y; Takayama T; Sagawa T; Takahashi Y; Ohnuma H; Okubo S; Shintani N; Tanaka S; Kida M; Sato Y; Ohta H; Miyanishi K; Sato T; Takimoto R; Kobune M; Yamaguchi K; Hirata K; Niitsu Y; Kato J
Cancer Chemother Pharmacol; 2010 Sep; 66(4):721-8. PubMed ID: 20041328
[TBL] [Abstract][Full Text] [Related]
13. A phase II study of biweekly S-1 and paclitaxel (SPA) as first-line chemotherapy in patients with metastatic or advanced gastric cancer.
Jiang H; Qian J; Zhao P; Zhang X; Zheng Y; Mao C; Zheng Y; Chen L; Wang Y; Mou H; Fang W; Teng L; Xu N
Cancer Chemother Pharmacol; 2015 Jul; 76(1):197-203. PubMed ID: 26013324
[TBL] [Abstract][Full Text] [Related]
14. Phase I study of the sequential administration of S-1 and cisplatin for metastatic gastric cancer.
Baba E; Fujishima H; Kusaba H; Esaki T; Ariyama H; Kato K; Tanaka R; Mitsugi K; Shibata Y; Harada M; Nakano S
Anticancer Res; 2009 May; 29(5):1727-32. PubMed ID: 19443394
[TBL] [Abstract][Full Text] [Related]
15. Phase I study of docetaxel, cisplatin and S-1 in patients with advanced gastric cancer.
Hironaka S; Yamazaki K; Taku K; Yokota T; Shitara K; Kojima T; Ueda S; Machida N; Muro K; Boku N
Jpn J Clin Oncol; 2010 Nov; 40(11):1014-20. PubMed ID: 20603245
[TBL] [Abstract][Full Text] [Related]
16. Feasibility study of triplet combination chemotherapy of paclitaxel, cisplatin and S-1 for advanced gastric cancer.
Fujitani K; Hasegawa H; Hirao M; Kurokawa Y; Tsujinaka T
Anticancer Res; 2011 Sep; 31(9):3085-91. PubMed ID: 21868564
[TBL] [Abstract][Full Text] [Related]
17. A multi-center phase II study of S-1 plus paclitaxel as first-line therapy for patients with advanced or recurrent unresectable gastric cancer.
Lee JJ; Kim SY; Chung HC; Lee KH; Song HS; Kang WK; Hong YS; Choi IS; Lee YY; Woo IS; Choi JH
Cancer Chemother Pharmacol; 2009 May; 63(6):1083-90. PubMed ID: 18813927
[TBL] [Abstract][Full Text] [Related]
18. Phase I/II study of a combination of S-1 and weekly paclitaxel in patients with advanced or recurrent gastric cancer.
Kawabata R; Fujiwara Y; Doki Y; Fujita J; Tsukahara Y; Yamasaki M; Miyata H; Takiguchi S; Monden M
Oncology; 2007; 72(3-4):219-25. PubMed ID: 18176087
[TBL] [Abstract][Full Text] [Related]
19. Phase II study of S-1 monotherapy in paclitaxel- and cisplatin-refractory gastric cancer.
Lee SJ; Cho SH; Yoon JY; Hwang JE; Bae WK; Shim HJ; Chung IJ
Cancer Chemother Pharmacol; 2009 Dec; 65(1):159-66. PubMed ID: 19479256
[TBL] [Abstract][Full Text] [Related]
20. A phase I combination chemotherapy study of biweekly paclitaxel and S-1 administration in patients with advanced gastric cancer.
Hokita S; Aikou T; Miyazono F; Ishigami S; Aridome K; Maenohara S; Saihara T; Suenaga K; Nomura H; Maeda S; Takatori H; Arima H; Uchikado Y; Natsugoe S; Takao S
Cancer Chemother Pharmacol; 2006 Jun; 57(6):736-40. PubMed ID: 16163539
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
